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Summary. Among all inflammatory cells involved in
COPD, those with a cytolytic or elastolytic activity are
thought to play a key role in the pathogenesis of the
disease. However, there is no data about the infiltration
of cells expressing the CD57 marker in small airways
and parenchyma of COPD patients.
In this study, surgical specimens from 43 subjects
undergoing lung resection due to lung cancer (9 non-
smokers, 18 smokers without COPD and 16 smokers
with moderate COPD) and 16 patients undergoing
double lung transplantation for very severe COPD were
examined. CD57+ cells, neutrophils, macrophages and
mast cells infiltrating bronchioles (epithelium, smooth
muscle and connective tissue) and parenchymal
interstitium were localized and quantified by
immunohistochemical analysis.
Compared to the other groups, the small airways of
very severe COPD patients showed a significantly
higher density of CD57+ cells, mainly infiltrated in the
connective tissue (p=0.001), and a significantly higher
density of neutrophils located characteristically in the
epithelium (p=0.037). Also, the density of neutrophils
was significantly higher in parenchyma of very severe
COPD patients compared with the rest of the groups
(p=0.001). Finally, there were significant correlations
between the bronchiolar density of CD57+ cells and the
FEV1 values (R=-0.43, p=0.022), as well as between the
parenchymal density of neutrophils and macroscopic
emphysema degree (R=0.43, p=0.048) in COPD groups.
These results show that CD57+ cells may be
involved in COPD pathogenesis, especially in the most
severe stages of the disease.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a
major health problem which is expected to be the third
leading cause of death worldwide by 2020 (López et al.,
2006). COPD is defined as a progressive and not fully
reversible airflow limitation, which is associated with an
abnormal inflammatory response of the lung to noxious
particles and gases, mainly cigarette smoke (Global
Initiative for Chronic Obstructive Pulmonary Disease,
GOLD, 2010). Although cigarette smoking is the most
commonly encountered risk factor in COPD, others
including genetic susceptibility, oxidative stress and
respiratory infections are thought to contribute to the
pathogenesis of the disease (GOLD, 2010). The
characteristic chronic inflammatory pattern (mono-
nuclear infiltration and tissue remodeling) in COPD
affects mainly small airways and lung parenchyma,
resulting in bronchiolitis and emphysema development. 
Several types of inflammatory cells, belonging both
to the innate and the adaptive immune systems, are
thought to be implicated in the complex inflammatory
status of COPD. Among these cells, those with cytolytic
or elastolytic capability are relevant in COPD
pathogenesis, due to their role in enhancement of the
inflammatory response and development of emphysema
(Barnes and Cosío, 2006). 
Increased numbers of CD8+ cells have been
documented in pulmonary tissue of COPD patients,
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which correlated with lung function parameters and
disease severity (O’Shaughnessy et al., 1997; Saetta et
al., 1999; Hogg et al., 2004; Olloquequi et al., 2010).
Furthermore, a recent study (Urbanowicz et al., 2010)
has shown a higher proportion and an increased lytic
activity of NK cells and NKT-like cells in the induced
sputum of COPD patients as compared to non-smokers
and smokers without COPD. However, very little is
known about the possible role that other cells with a
cytolytic potential, such as cells expressing CD57, could
play in COPD. CD57 is a marker of terminally
differentiated cells with a killer activity (Brenchley et
al., 2003; Focosi and Petrini, 2007; Chattopadhyay et al.,
2009). It has been demonstrated that CD57+ cells
infiltrating lung tissue of smokers both with and without
COPD express granzymes A and B (Vernooy et al.,
2007), and a high density of these cells have been found
in both the bronchial mucosa (Di Stefano et al., 1998)
and lung lymphoid follicles (Olloquequi et al., 2011) of
COPD patients. Although these findings point to an
involvement of CD57+ cells in the pathology of COPD,
there is no data about the density and distribution of
these cells in the two main compartments affected in the
disease, i.e., small airways and lung parenchyma. 
Regarding the involvement of elastolytic cells in
COPD, the hypothesis that neutrophils and macrophages
play a key role in the pathogenesis of the disease is one
of the most widely accepted. However, the results
published to date are not conclusive, since some findings
show significantly increased numbers of neutrophils or
macrophages in small airways and lung parenchyma of
COPD patients (Finkelstein et al., 1995; Grashoff et al.,
1997; Pilette et al., 2001; Retamales et al., 2001; Turato
et al., 2002), while other findings rule out a relationship
between these cells and the disease (Bosken et al., 1992;
Lams et al., 1998; Saetta et al., 1998; Saetta et al., 1999;
Majó et al., 2001). The lack of conclusive results could
be largely due to the scarcity of data from the group of
very severe COPD patients.
In order to shed light on these questions, our present
study systematically examines the densities and
localization of cells with cytolytic/elastolytic capabilities
infiltrating bronchiolar compartments and parenchymal
interstitium of moderate and very severe COPD patients. 
Materials and methods
Patients
The study population comprised 59 subjects who
underwent lung resection for non-obstructive peripheral
lung tumors or were subjected to double lung
transplantation for very severe COPD. The study was
approved by the Ethics Committee of the Vall d’Hebron
Hospital (Barcelona, Spain) and written informed
consent was obtained from all patients. Spirometry and
diffusing capacity measurements and body
plethysmography were performed to assess pulmonary
function using standard procedures (Crapo et al., 1995)
and equipment (Masterlab; Jaeger, Würzburg, Germany).
None of the subjects had had a COPD exacerbation
during a minimum of 3 weeks prior the surgery, nor had
received chemotherapy before surgery.
Patients were classified into 4 clinical groups
according to their smoking habits (smokers and non-
smokers) and COPD severity (GOLD, 2009): 9
nonsmoking patients (never smokers) with normal lung
function; 18 asymptomatic smokers with normal lung
function; 16 smokers with moderate COPD (GOLD
stage II); and 16 smokers with very severe COPD
(GOLD stage IV) undergoing lung transplantation. 
Sample processing
Immediately after surgery, the excised lungs or lobes
were inflated and fixed with 4% formaldehyde. After
fixation, surgical specimens were sliced and the severity
of emphysema (macroscopic emphysema degree, MED,
%) was graded using a panel grid as previously
described (Thurlbeck et al., 1970). After that, 2x2x0.3
cm randomly selected tissue blocks were excised,
embedded in paraffin, cut into 4-µm sections and
mounted on positive charged slides Starfrost Plus
(Menzel-Gläser, Braunschweig, Germany).
In samples from patients with non-obstructing
peripheral masses, sections were taken from sites
macroscopically free from tumor, always farther than 2
cm from the masses. A further microscopic examination
was also performed by an expert pathologist in order to
exclude a tumor infiltration in the sample.
Immunohistochemistry
The following antibodies were used at indicated
dilutions: monoclonal anti-CD57 (Clone TB01, 1:80;
DakoCytomation, Glostrup, Denmark), monoclonal anti-
CD68 (for macrophages, Clone KP1, 1:50;
DakoCytomation), monoclonal anti-Human Neutrophil
Elastase (Clone 121-3E10, 1:250; Calbiochem, San
Diego, USA) and monoclonal anti-Human Mast Cell
Tryptase (Clone AA1,1:800; DakoCytomation). Primary
antibody binding was detected using the ABC
immunoperoxidase method (Vectastain Elite ABC kit,
Burlingame, USA) with a DAB reaction. Negative
controls were carried out on parallel sections by
omission of the primary antibody and by substitution of
the primary antibody with the appropriate isotype
control (Negative control Mouse IgM, clone DAK-G08
and Negative control Mouse IgG1, clone DAK-G01,
Dako).
Cell counts
For the assessment of cell densities, the numbers of
cell profiles including a nucleus were counted and
expressed per tissue area, the last determined by point
counting, as previously described (Olloquequi et al.,
2010). Briefly, twelve fields were randomly and
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systematically sampled to assess cell densities in
parenchymal interstitium, while in small airways, several
non-overlapping fields were assessed until all the
available area of each bronchiole was covered. By using
a grid with a known area attached to the eye piece of the
microscope, the number of points hitting the tissue
compartment of interest (parenchymal interstitium and
bronchiolar epithelium, smooth muscle and adventitia)
were counted and converted into square millimeters. In
turn, for each field, the number of cells was determined
by counting the cell profiles that were not in vessels or
intersected by the exclusion lines. Mean patient values
were obtained by averaging the results of all fields. Cell
densities were expressed as number of cells per square
millimetres of tissue examined.
Statistical analysis
Descriptive statistical analysis included means and
standard errors for each parameter. Differences among
groups were analyzed using the analysis of variance
(ANOVA) for clinical data and the Kruskal-Wallis test
for cell densities. When differences in cell densities were
significant, the Kruskal-Wallis test was followed by the
Mann-Whitney U test for comparison between groups.
Correlations were calculated by Spearman’s rank
correlation test. Significance level was set at p<0.05. All
analyses were performed using Statgraphics Centurion
XV (StatPoint Inc., Virginia, USA).
Results
Demographic and clinical findings
Patient characteristics are presented in Table 1. The
four clinical groups were similar with regard to age and
no significant difference was found in pack-years among
smokers with and without COPD. As expected from the
selection criteria, non-smokers and smokers without
COPD had normal lung function, whereas patients with
COPD showed significant alterations in spirometry
parameters, such as FEV1, FEV1/FVC and DLCO.
Moreover, there was a significantly increased
macroscopic emphysema degree (MED, %) in COPD
patients, especially those in very severe GOLD stage
(Table 1).
Immunohistochemistry
Small airways
In all patients, the density of CD57+ cells,
neutrophils, macrophages and mast cells was assessed in
the entire bronchiolar wall, as well as in the bronchiolar
epithelium, connective (subepithelial and adventitial)
and smooth muscle layers. Results are summarized in
Table 2 and Fig. 1.
Patients with very severe COPD showed a
significantly higher density of CD57+ cells in small
airways than non-smokers and smokers without COPD
(p=0.021, Table 2, Fig. 1A,B). Furthermore, the density
of neutrophils was significantly increased in the
bronchiolar wall of very severely diseased patients when
compared with the rest of the groups (p=0.049, Table 2). 
The assessment of each bronchiolar compartment
revealed a significantly higher density of neutrophils in
the epithelium of very severe COPD patients compared
with the rest of the groups (p=0.037, Table 2, Fig. 1C,D).
Although the difference was not statistically significant,
the density of CD57+ cells, macrophages and mast cells
was also higher in the epithelium of COPD patients
compared to patients without COPD. 
Regarding the bronchiolar connective tissue, there
was a significantly increased density of CD57+ cells in
very severe COPD patients compared to the rest of the
groups (p=0.001, Table 2). No differences were found
among clinical groups for the other inflammatory cells in
the connective compartment. Therefore, the small
airways of very severe COPD patients are characterized
by two kinds of cell infiltration: an epithelial infiltrate of
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Table 1. Clinical and demographical data.
Non-smokers (n=9) Smokers without COPD (n=18) Moderate COPD (n=16) Very severe COPD (n=16)
Sex, Male / Female 1 / 8 14 /4 16 / 0 13 / 3 
Age, years 61.78±4.62 60.94±2.58 63.34±2.01 55.93±1.34
Smoking history, pack-years 0.00±0.00 49.89±5.86 61.44±5.35 47.87±5.72
Smoking status, current / ex-smoker - 6 / 12 9 / 7 1 / 15 
Inhaled corticosteroids use, yes / no 1 / 8 1 / 17 7 / 9 14 / 2 
FEV1, % predicted 99.34±8.16 84.98±2.57 69.34±4.52*† 20.78±1.22*†‡
FEV1/FVC, % predicted 80.07±2.77 78.99±1.86 61.78±4.64*† 35.18±2.01*†‡
RV, % predicted 107.53±10.17 98.08±7.69 146.06±7.82 282.65±23.02*†‡
TLC, % predicted 101.02±2.82 90.5±3.75 113.76±3.70 135.17±9.00*†‡
DLCO, % predicted 82.13±7.86 71.62±4.21 57.56±3.03*† 34.79±4.01*†‡
MED, % predicted 1.67±1.10 13.89±3.81 59.14±1.99*† 67.50±4.03*†‡
Definition of abbreviations: FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; RV: residual volume; TLC: total lung capacity;
DLCO: carbon monoxide diffusing capacity; MED: macroscopic emphysema degree. Values expressed as mean ± SEM. *: Different from control non-
smokers (p<0.001). †: Different from smokers without COPD (p<0.001). ‡: Different from moderate COPD patients (p<0.001).
neutrophils near airway lumen, and another of CD57+
cells located deeper in the connective tissue.
Finally, the infiltration in smooth muscle was
minimal and no statistical differences were observed
among the four groups (Table 2).
Parenchymal interstitium
When the density of inflammatory cells was
assessed in lung parenchymal interstitium, it was found
that very severe COPD patients had a higher number of
neutrophils per square millimeter of parenchymal
interstitium than the other groups (p=0.001, Table 2).
Although the density of CD57+ cells was also higher in
patients with very severe COPD, no statistical
differences were found for these cells, neither for
macrophages nor mast cells, among clinical groups
(Table 2).
Correlations
When moderate and very severe patients were
considered as one group, some significant correlations
were found between cell densities and clinical data. The
density of CD57+ cells in the bronchiolar wall was
inversely correlated with FEV1 (% of predicted) values
(R=-0.43, p=0.022). Moreover, the density of neutrophils
in parenchymal interstitium was significantly correlated
with the FEV1 (R=-0.46, p=0.041) and with the
macroscopic emphysema degree values (R=0.43,
p=0.048).
Finally, although the correlations were maintained
when all smokers were considered as a group, the values
were, mainly, lower than those found when only COPD
patients were grouped. There was an inverse correlation
between the density of bronchiolar CD57+ cells and the
FEV1 (% of predicted) values (R=-0.36, p=0.003).
Moreover, the density of neutrophils in the bronchiolar
wall was also correlated with a decrease in FEV1 values(R=-0.44, p=0.006). With reference to parenchymal
interstitium, there was an inverse correlation between the
density of neutrophils and the FEV1 values (R=-0.37,
p=0.026) as well as with the macroscopic emphysema
degree (R=0.49, p=0.002).
Discussion
Our present study shows for the first time that very
severe COPD patients have a significantly higher density
of CD57+ cells and neutrophils in small airways than
non-smokers and smokers without COPD. Furthermore,
the bronchiolar density of these cells is inversely
correlated with the FEV1 (% of predicted) values.
Additionally, our results show a significant increase of
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Table 2. Bronchiolar and parenchimal densities of innate immune cells.
Non-smokers Smokers without Moderate Very severe
(n=9) COPD (n=18) COPD (n=16) COPD (n=16)
Bronchiolar wall
CD57+, cells/mm2 0.00 (0.00-21.66) 6.91 (0.00-60.00) 8.75 (0.00-118.18) 26.67 (0.00-78.57) *†
CD68+ (Macrophages), cells/mm2 142.79 (68.06-236.07) 126.86 (26.20-339.66) 152.51 (41.66-236.07) 120.10 (48.33-324.97)
Elastase+ (Neutrophils), cells/mm2 0.00 (0.00-0.00) 6.30 (0.00-65.60) 2.37 (0.00-15.85) 46.82 (0.00-238.14) *†‡
Tryptase+ (Mast cells), cells/mm2 155.11 (102.65-367.14) 187.03 (70.00-328.17) 209.09 (33.75-506.99) 204.12 (43.21-400.83)
Bronchiolar epithelium
CD57+, cells/mm2 0.00 (0.00-16.66) 0.00 (0.00-100.00) 4.51 (0.00-366.66) 8.33 (0.00-105.66)
CD68+ (Macrophages), cells/mm2 13.72 (0.00-45.47) 45.86 (0.00-311.55) 50.00 (8.33-262.38) 63.00 (0.00-129.00)
Elastase+ (Neutrophils), cells/mm2 0.00 (0.00-0.00) 12.05 (0.00-100.00) 14.28 (0.00-125.00) 91.53 (0.00-396.87) *†‡
Tryptase+ (Mast cells), cells/mm2 34.22 (10.11-112.37) 50.00 (7.50-212.05) 101.85 (12.50-152.11) 103.85 (0.00-350.00)
Bronchiolar smooth muscle
CD57+, cells/mm2 0.00 (0.00-0.00) 0.00 (0.00-0.00) 0.00 (0.00-12.00) 0.00 (0.00-12.50)
CD68+ (Macrophages), cells/mm2 0.00 (0.00-10.00) 0.00 (0.00-33.00) 1.66 (0.00-90.92) 1.92 (0.00-18.19)
Elastase+ (Neutrophils), cells/mm2 0.00 (0.00-3.20) 0.00 (0.00-12.16) 0.00 (0.00-17.02) 0.00 (0.00-15.22)
Tryptase+ (Mast cells), cells/mm2 5.55 (0.00-526.58) 0.00 (0.00-556.67) 0.00 (0.00-60.00) 0.00 (0.00-11.11)
Bronchiolar connective tissue
CD57+, cells/mm2 0.00 (0.00-25.00) 2.20 (0.00-72.98) 9.52 (0.00-64.43) 25.00 (0.00-92.50) *†‡
CD68+ (Macrophages), cells/mm2 219.69 (96.89-531.31) 191.65 (20.35-510.56) 250.46 (41.66-511.12) 96.26 (36.57-462.06)
Elastase+ (Neutrophils), cells/mm2 0.00 (0.00-0.00) 6.44 (0.00-96.66) 5.18 (0.00-83.35) 13.75 (0.00-151.25)
Tryptase+ (Mast cells), cells/mm2 310.26 (154.49-494.52) 278.59 (91.51-472.22) 330.91 (41.66-647.97) 235.41 (86.21-504.13)
Parenchymal interstitium
CD57+, cells/mm2 14.16 (1.81-75.75) 11.01 (0.00-80.95) 8.33 (0.00-76.42) 23.00 (0.00-56.89)
CD68+ (Macrophages), cells/mm2 9.31 (0.00-33.68) 11.92 (0.00-51.54) 12.38 (0.00-78.80) 8.09 (0.00-28.97)
Elastase+ (Neutrophils), cells/mm2 2.38 (0.00-18.89) 2.70 (0.00-15.39) 2.65 (0.00-20.02) 4.25 (0.00-21.42)*†‡
Tryptase+ (Mast cells), cells/mm2 109.67 (32.91-271.65) 106.46 (33.64-208.33) 101.49 (17.16-220.71) 122.96 (0.00-267.98)
Values expressed as median (range). *: Different from control non-smokers (p<0.05). †: Different from smokers without COPD (p<0.05). ‡: Different
from moderate COPD patients (p<0.05).
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Fig. 1. Immunolocalization of CD57+ cells and neutrophils in peripheral lung tissue. A, B. CD57+ cells infiltrating small airways of a control smoker (A)
and a patient with very severe COPD (B). Very severe COPD patients showed a significantly higher infiltration of CD57+ cells in the bronchiolar
connective tissue compared to the rest of the groups (p=0.001). Inset in (B) represents a close-up image of bronchiolar CD57+ cells. C, D. Infiltration of
neutrophils in a small airway of a non-smoker (C) and a patient with very severe COPD (D). The density of neutrophils in the epithelial layer was higher
in very severe COPD compared to the rest of the groups (p=0.037). E, F. Neutrophil infiltration in lung parenchyma of a non-smoker (E) and a patient
with very severe COPD (F). The density of neutrophils was higher in parenchymal interstitium of very severe COPD patients than in the rest of the
groups (p=0.001). Sections were counterstained with Friedlander’s haematoxylin. Scale bars: A, B, 75 µm; C, D, 25 µm; E, F, 50 µm.
neutrophils in parenchymal interstitium of very severe
COPD patients, which is also correlated with both the
FEV1 and with the degree of macroscopic emphysema.
The CD57 epitope was first described to be
selectively expressed on human NK and NK T cells
(Abo and Balch, 1981). Importantly, in light of recent
findings, CD57 appears to be a good marker of
differentiated inflammatory cells with cytolytic activity.
It has been demonstrated that CD57 expression is
strongly correlated with a simultaneous expression of
pro-apoptotic molecules, such as granzyme A, granzyme
B and perforin in peripheral blood mononuclear cells
(Chattopadhyay et al., 2009). Parallel to this, it is
noteworthy that Vernooy et al. (2007) showed that
CD57+ cells infiltrating lung tissue of smokers with and
without COPD express granzymes A and B. 
To the best of our knowledge, this is the first study
providing data on CD57+ cell density in small airways
and lung parenchyma of COPD patients. We have found
a significant increase of these cells in small airways of
very severe COPD patients compared to smokers
without COPD and non-smokers. Moreover, the
assessment of each bronchiolar compartment allowed us
to observe that CD57+ cells were mainly infiltrated in
the bronchiolar connective tissue. These data extend the
previous findings of Di Stefano et al. (1998), who found
increased CD57+ cells in bronchial subepithelium of
severe COPD subjects, as well as extending the findings
of our previous study (Olloquequi et al., 2011) reporting
an increased density of CD57+ cells in lung lymphoid
follicles in COPD. In addition to the aforementioned
alterations in cell population, our results show an inverse
correlation between the bronchiolar density of CD57+
cells and the FEV1 values, concurring with the results
obtained by Di Stefano et al. (1998) in large airways.
However, our results show no statistical differences in
parenchymal CD57+ cells among groups, unlike our
results obtained in small airways.
Athough our findings do not show a higher density
of pulmonary CD57+ cells in smokers without COPD
compared to non-smokers, it is known that smoking per
se increases the number of inflammatory cells in lung
tissue (Tanni et al., 2010). This suggests that, although
the inflammatory pattern initiated by cigarette smoke
could induce the recruitment of cytolitic cells in the
lungs, other stimuli are also required to enhance the
infiltration of CD57+ cells.
As CD57 is mainly expressed on activated cytolytic
cells, one question emerges from our results: which
mechanisms are involved in the activation of these cells?
It has been recently reported that dendritic cells can
enhance NK cell cytotoxicity through Jagged2-Notch
interaction in a murine model (Kijima et al., 2008).
Furthermore, although some authors reported that
cigarette smoke may suppress dendritic cell maturation
(Tsomakidou et al., 2009) others have shown an increase
of dendritic cells in lung tissue of COPD patients (Van
Pottelberge et al., 2010; Vassallo et al., 2010). Thus, it is
conceivable that an accumulation of dendritic cells in
lung could account for an activation of NK and NK T
cells.
Although there is evidence pointing toward CD57 as
a marker of lung inflammation (Palmer et al., 2007), it is
difficult to discuss the functional consequences of the
presence of CD57+ cells in COPD, since studies of these
cells in respiratory diseases are scarce. However, both
the population increase of CD57+ cells in bronchioles of
very severely diseased patients and the inverse
correlation with FEV1 suggest an important role for
these cells in COPD pathogenesis. CD57+ cells may act
by promoting an inflammatory status in small airways of
COPD patients, as was proposed for CD8+ or B-
lymphocytes (Barnes and Cosio, 2006; Olloquequi et al.,
2010), through the release of some inflammatory
mediators. For instance, cells expressing CD57 are
capable of immediate functional activity by producing
IFN-γ and TNF-α (Freeman et al., 2010). Moreover,
CD57+ cells express granzyme A, a serine protease that
can directly activate certain cytokines (Irmler et al.,
1995), as well as induce secretion of IL-6 and IL-8 (two
major mediators of the inflammatory response) in lung
fibroblasts, among other cell types (Sower et al.,
1996a,b). In addition, this hypothesis for a role of
CD57+ cells in enhancing the inflammatory response in
COPD is reinforced by the increase of CD57 expression
observed during chronic immune activation (Tarazona et
al., 2000). Nevertheless, since the percentage of CD57+
cells increases in some infectious diseases (Focosi et al.,
2010), it is also possible that the increased bronchiolar
density of CD57+ cells in COPD may occur in response
to repeated and worsening viral or bacterial infections,
which are frequent in COPD patients (Di Stefano et al.,
1998; Sethi and Murphy, 2008). 
Regarding the distribution of other key cells in
COPD pathogenesis, either by their elastolytic activity
and/or by their inflammatory potential, the present study
provides relevant data on a seldom studied group:
patients submitted to double lung transplantation for
very severe COPD. Concurring with previous studies
(Bosken et al., 1992; Lams et al., 1998; Saetta et al.,
1998, 1999; Turato et al., 2002), our results showed no
significant differences in bronchiolar or parenchymal
densities of macrophages and mast cells among patients
with or without COPD. However, there are studies
(Finkelstein et al., 1995; Grashoff et al., 1997;
Retamales et al., 2001; Turato et al., 2002; Andersson et
al., 2010) reporting increased numbers of these cells in
small airways or lung parenchyma of COPD patients.
These contradictory findings may be attributable to the
origin of the samples and the different clinical groups
considered. By contrast, we have found a significant
increase of neutrophils in both small airways and
parenchymal interstitium of very severe COPD patients
compared with the other groups. Moreover, both the
bronchiolar and the parenchymal densities of neutrophils
correlated with a decrease of FEV1, whereas a positive
correlation was found between parenchymal neutrophils
and the degree of macroscopic emphysema. Although an
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inverse relationship between neutrophils and FEV1 hasbeen reported in large airways of COPD patients
(O’Shaughnessy et al., 1997; Di Stefano et al., 1998;
Baraldo et al., 2004), to the best of our knowledge, this
is the first study describing a similar correlation in small
airways and lung parenchyma in COPD.
Our results from very severely diseased patients
(GOLD stage IV) extend the results of previous studies
reporting high numbers of neutrophils in bronchioles
(Pilette et al., 2001) and parenchyma (Retamales et al.,
2001) obtained in severe COPD. In one of these studies,
Retamales et al. (2001) described a relationship between
the number of neutrophils in parenchymal tissue and the
amount of emphysematous destruction assessed by
computed tomography.
Despite these results, there are also studies showing
no differences in bronchiolar (Bosken et al., 1992;
Grashoff et al., 1997; Lams et al., 1998; Saetta et al.,
1998; Turato et al., 2002) or parenchymal (Saetta et al.,
1999) densities of neutrophils among patients with or
without COPD. 
These inconclusive results could be explained by the
short lifespan of the infiltrating neutrophils (O’Donnell
et al., 2006). Furthermore, unlike our present work, none
of the aforementioned studies included a group of
patients with very severe COPD (GOLD stage IV).
Although all the patients enrolled in our study were in a
stable condition, it is conceivable that an increase in
neutrophil density may be more easily detected in very
severe COPD patients, since these subjects are likely to
suffer repeated infections which could enhance the
recruitment of neutrophils to lung tissue (Sower et al.,
1996; Retamales et al., 2001). In any event, neutrophils
have been largely related to airway inflammation and
parenchymal destruction in COPD (O’Donnell et al.,
2006; Di Stefano et al., 2009; Murugan and Peck, 2009).
Hence, our results of increased neutrophil densities in
both small airways and parenchyma in very severe
COPD patients, together with their correlation with
FEV1 and emphysema, contribute new evidence to the
arguments for a key role of these cells in COPD.
The possibility that corticosteroids treatment could
have influenced the numbers of inflammatory cells
should be taken into account, since most patients in our
study received inhaled steroids. Indeed, it is known that
corticosteroids may decrease the apoptosis of neutrophils
in vitro (Liles et al., 1996; Cox and Austin, 1997).
Moreover, Gizycki et al (2002) showed a significant
increase of neutrophils in bronchial biopsies of COPD
patients treated with inhaled corticosteroids as compared
to those treated with placebo. However, there are also
studies showing no significant differences in airway
neutrophil counts between inhaled corticosteroids-
treated and placebo-treated asthmatics (Hoshino and
Nakamura, 1996; Nguyen et al., 2005), and even a
reduction of neutrophil counts have been found in
sputum of COPD patients treated with inhaled
corticosteroids versus those treated with placebo (Yildiz
et al., 2000). Although it has been shown that steroid
therapy drastically lowers lymphocyte numbers in lung
tissue (Reid et al., 2008), no data are available about the
effect of inhaled steroids on infiltrated CD57+ cells.
Nevertheless, Palmer et al. (2007) reported no
differences in CD57 expression on blood and BAL T
lymphocytes between corticosteroid-treated subjects and
corticosteroid-untreated subjects with beryllium-induced
disease. Therefore, the hypothetical effect of inhaled
steroids on these inflammatory cells requires further
study. 
A potential bias in our study is that moderate COPD
patients and control groups had peripheral lung cancer
whereas very severe COPD patients did not, and there is
evidence that lung cancer can influence T cell
differentiation (Reepert et al., 2010). However,
Domagala-Kulawik et al. (2003) reported no significant
differences in CD57+ cell counts on bronchoalveolar
lavage fluid among patients with peripheral lung tumors
and control smokers and non-smokers. Moreover, it has
been reported that metastasis-free regional lymph nodes
draining different human epithelial tumors present a
reduction in almost all immune cells, except CD57+ cells
(Di Girolamo et al., 2008). Taken together, we believe
that our present results are valid.
In summary, our study shows that very severe COPD
patients have an increased density of CD57+ cells in
small airways, as well as an increased density of
neutrophils in both small airways and parenchymal
interstitium. Moreover, the number of these cells is
correlated with the FEV1 and the macroscopic
emphysema degree values, which suggests a possible
role for CD57+ cells and neutrophils in the pathogenesis
of COPD.
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